Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial

被引：1
|
作者：
Xiao, Y. [1 ]
Cheng, H. [2 ,3 ]
Wang, L. [1 ]
Yang, L. [1 ]
Yu, X. [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
562P
引用
收藏
页码：S805 / S805
页数：1
相关论文
共 50 条
  • [1] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [2] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
  • [3] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
    Lan, Chunyan
    Huang, Xin
    Shen, Jing-Xian
    Wang, Yin
    Xiong, Ying
    Li, Jundong
    Cao, Xinping
    Deng, Yanhong
    He, Mian
    Zou, Guorong
    Wang, Xiaodi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
    Chen, Jie
    Li, Chen
    Cao, Yuanjie
    Zhu, Li
    Zhang, Bailin
    You, Jinqiang
    Hou, Hailing
    Wang, Jing
    Yuan, Zhiyong
    BMC CANCER, 2022, 22 (01)
  • [5] Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
    Jie Chen
    Chen Li
    Yuanjie Cao
    Li Zhu
    Bailin Zhang
    Jinqiang You
    Hailing Hou
    Jing Wang
    Zhiyong Yuan
    BMC Cancer, 22
  • [6] Concurrent Chemoradiotherapy plus Programmed Death-1 (PD-1) Blockade for Locally Advanced Cervical Cancer: Preliminary Results of a Single-Arm, Open -Label, Phase II Trial
    Xue, J.
    Shi, R.
    Ma, J.
    Liu, Z.
    Feng, G.
    Chen, Q. Q.
    Li, Y.
    He, Y.
    Ji, S.
    Shi, J.
    Zhu, X.
    Zhou, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E542 - E543
  • [7] Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study.
    Jia, Ruinuo
    Zhang, Junqian
    Zhang, Yaowen
    Li, Shuoguo
    Sheng, Manxi
    Ma, Jianguang
    Zheng, Anping
    Tian, Chuntao
    Wang, Jianli
    Li, Liuyan
    Gao, Shegan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 371 - 371
  • [8] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
  • [9] Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
    Chen, Xiaofeng
    Wu, Xiaofeng
    Wu, Hao
    Gu, Yanhong
    Shao, Yang
    Shao, Qianwen
    Zhu, Feipeng
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Zhao, Fengjiao
    Mao, Weidong
    Sun, Jing
    Wang, Jian
    Han, Gaohua
    Li, Changxian
    Xia, Yongxiang
    Seesaha, Poshita Kumari
    Zhu, Dongqin
    Li, Huajun
    Zhang, Junling
    Wang, Guoqiang
    Wang, Xuehao
    Li, Xiangcheng
    Shu, Yongqian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [10] Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): A prospective, single-arm, phase II trial
    Chen, J.
    Li, K.
    Han, Y.
    Shen, Y.
    Wang, Y.
    Song, K.
    Chen, X.
    Xia, B.
    Zou, D.
    Wang, Y.
    Ma, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S804 - S804
12345